medigraphic.com
Boletín Médico del Hospital Infantil de México

2010, Number 1

<< Back Next >>

Bol Med Hosp Infant Mex 2010; 67 (1)

Successfully evolution of premature triplets with systemic neonatal candidiasis treated with caspofungin

Granados-Perales DE, Ugalde-Fernández JH

Language: Spanish
References: 22
Page: 52-57
PDF size: 105.96 Kb.


ABSTRACT

Background: Infections caused by Candida sp. have been significantly increasing in patients in neonatal intensive care units (NICU) and are the most common causes of morbi-mortality in this population group. Amphotericin B has been considered to be the standard antifungal therapy. However, it has been associated with adverse effects such as persistent fungemia due to the increase of Candida resistance, in particular the non-albicans species, similar to the resistance shown by other antifungals such as fluconazol.
Clinical cases: Triplets of gestational age of 29 weeks received advanced life support in the NICU, including mechanical ventilation (MV), insertion of venous catheters, total parenteral nutrition (TPN) and multiple regimes of broad-spectrum antibiotics. The three patients developed C. parapsilosis sepsis. Antifungal therapy was initiated with fluconazol prior to the use of conventional amphotericin B and liposomal amphotericin B. There was no clinical improvement and blood cultures remained positive. Clinical improvement was noted after the initiation of caspofungin (2 mg/kg/day) in addition to the use of liposomal amphotericin B. The triplets recovered completely with adequate tolerance to the medication and without adverse effects.
Conclusion: Use of caspofungin proved to be an effective and well-tolerated therapy in these patients (2 mg/kg/day). It can be considered an alternative treatment for invasive candidiasis in premature neonates, although optimal dosage remains undetermined.


REFERENCES

  1. Rodríguez D, Almirante B, Park BJ, Cuenca-Estrella M, Planes AM, Sánchez F, et al. Candidemia in neonatal intensive care units. Pediatr Infect Dis J 2006;25:224-229.

  2. Bendel CM. Nosocomial neonatal candidiasis. Pediatr Infect Dis J 2005;24:831-832.

  3. Odio CM, Araya R, Pinto LE, Castro LE, Vasquez S, Alfaro B, et al. Caspofungin therapy of neonates with invasive Candidiasis. Pediatr Infect Dis J 2004;23:1093-1097.

  4. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. Prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634–643.

  5. Benjamin DK Jr, Pool C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic thecniques. Pediatrics 2003;112:634–640.

  6. Rangel-Frausto MS, Wilbin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National Epidemiology of Mycosis Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253–258.

  7. Zaoutis TE, Coffin FE, Chu JH, Heydon K, Zhao H, Greves Hm, et al. Risk Factors for mortality in children with candidemia. Pediatr Infect Dis J 2005;24:736-739.

  8. Karthaus M, Cornely OA. Treatment options in candidaemia. Mycoses 2007;50(Suppl 1):44-49.

  9. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-777.

  10. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety, and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001;10: 1545–1558.

  11. Smith PB, Steinbach WJ, Cotton CM, Schell WA, Perfect JR, Walsh TJ, et al. Caspofungin for the treatment of azole resistant candidaemia in a premature infant. J Perinatol 2007;27:127-129.

  12. Michel IM, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health-System Pharm 2006;63(18 pt 1):1693-1703.

  13. Michel IM, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health-System Pharm 2006;63(19 pt 2):1813-1820.

  14. McCormack PL, Perry CM. Caspofungin: A review of its use in the treatment of fungal infections. Drugs 2005;65:2049-2068.

  15. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005;18:484-489.

  16. Frattarelli DA, Reed MD, Wiacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004;64:949-968.

  17. Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungical therapy. Pediatr Infect Dis J 2005;24:921-923.

  18. Kauffman CA. New antifungal agents. Sem Respir Crit Care Med 2004;25:233-239.

  19. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445–1457.

  20. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003;51:513–521.

  21. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003;19:263–271.

  22. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–189.




2020     |     www.medigraphic.com